Antifungal Treatment Market Research Report- Global Forecast till 2023

Report / Search Code: MRFR/HC/1097-CRR  
Publish Date: August, 2017

Price
1-user PDF : $ 4450.0  
Enterprise PDF : $ 6250.0

Description:

Antifungal Treatment Market Information, By Drugs Class (Azoles, Pyrimidines, Echinocandins, Polyenes, Allylamines, And Others), By Therapeutic Indication (Systemic, Candidiasis, Coccidioidomycosis, Cryptococcosis, And Prophylactic), By Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides Immitis, Zygomycetes, Trichophyton, And Others), And By End Users (Hospitals & Clinics, Dermatology Clinics, And Others) - Global Forecast Till 2023

Market synopsis of global anti-fungal treatment market:

Market Scenario

Fungal infections such as athlete's foot, ringworm infection, serious systemic infections, and others are spreading rapidly across the globe and a number of treatments are available to treat these diseases. Rising incidence of immunological disease and availability of a wide range of products have driven the growth of the global antifungal treatment market. Furthermore, rising awareness about side effects of traditional drugs and availability of new drugs favor the growth of the market.

The global antifungal treatment market is expected to grow at a CAGR of 4.61% during the forecast period and is estimated to reach USD 19,558.0 million by 2023.

FIGURE 1                   Global antifungal treatment market by drug class 2016 (%)

Key Players in the Global Antifungal Treatment Market

Some of the key players in this market are Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany)

Segments

The global antifungal treatment market has been segmented on the basis of drugs class, which includes azoles, pyrimidines, echinocandins, polyenes, allylamines, and others drugs.

On the basis of therapeutic indication, the market is segmented into systemic, candidiasis, coccidioidomycosis, and cryptococcosis.

On the basis of pathogen, the market is segmented into Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, and others.

On the basis of end users, the market is segmented into hospitals & clinics, dermatology
clinics and other users.

Research Methodology:

Regional Analysis of Global Antifungal Treatment Market

Considering the global scenario of the market, the Americas accounted for a significant market share in 2016, which was valued at USD 5,539.4 million as a result of increasing prevalence of immunological diseases and rising healthcare expenditure.

Europe is the second largest market and holds a noticeable share in the global antifungal treatment market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities, skilled medical professionals, and adoption of new therapies.

Increasing prevalence of HIV in Asia Pacific region is the key factor for the market growth. Rising awareness about the antifungal treatment and availability of new treatment methods drive the market in Asia Pacific region. In Asia Pacific, the market shows growth opportunities in China and India. China is expected to be the fastest growing market with the CAGR of 5.24% during the forecasted period.

The Middle East & Africa is expected to show the least growth in this market due to some major factors such as lack of awareness about the anti-fungal treatment, limited access and availability of treatment facilities, low income etc.

Key Findings

- Azoles segment in drug class held the largest market share in 2016, which was valued at USD 2,312.6 million in 2016
- Systemic segment in therapeutics indication held the largest market share in 2016.
- Asia Pacific region is expected to be the fastest growing market at the CAGR of 4.88% during the forecasted period.

The report on the Global Anti-fungal Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Intended Audience:

- Antifungal drug manufacturers
- Antifungal drug suppliers
- Medical research laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

TABLE OF CONTENTS

1 Industry Analysis
2 Report Prologue
  2.1 Key Recommendation
  2.1.1 Introduction
  2.1.1.1 Identify New Opportunities
  2.1.1.2 Competitive Analysis
  2.1.1.3 Funding
  2.1.1.4 Market by Pathogen
3 Market Introduction
  3.1 Scope of Study
  3.2 Research Objective
  3.3 Assumptions & Limitations
    3.3.1 Assumptions
    3.3.2 Limitations
  3.4 Market Structure
4 Research Methodology
  4.1 Research Process
  4.2 Primary Research
  4.3 Secondary Research
  4.4 Market Size Estimation
    4.4.1 Market Share analysis
  4.5 Market Pricing Approach
5 Market Dynamics
  5.1 Introduction
  5.2 Drivers
    5.2.1 Increasing Incidents of Fungal Infections
    5.2.2 Increasing Prevalence of Immunological Diseases
    5.2.3 Availability of Wide Range of Products
    5.2.4 Increasing Awareness about the Fungal Infections
  5.3 Restraints
    5.3.1 Side-Effects of Treatment
    5.3.2 Presence of Misbranded and Spurious Drugs
  5.4 Opportunities
    5.4.1 Development of New Drugs
    5.4.2 Increasing Government Support
  5.5 Mega Trends
    5.5.1 Focus of Development of Treatment for Systemic Mycosis
    5.5.2 Treatment for HIV-Linked Cryptococcal Meningitis
  5.6 Macroeconomic Indicators
  5.7 Technology Trends & Assessment
  5.8 Industrial SWOT
    5.8.1 Strengths
    5.8.2 Weaknesses
    5.8.3 Opportunities
    5.8.4 Threats
6 Global Antifungal Treatment Market, by Drug Class
  6.1 Introduction
  6.2 Azoles
  6.3 Echinocandins
  6.4 Polenes
  6.5 Allylamines
  6.6 Pyrimidines
  6.7 Others
7 Global Antifungal Treatment Market, by Therapeutic Indications
  7.1 Introduction
  7.2 Systemic
  7.3 Cryptococcosis
8.5 Prophylactic Use of Antifungals
8.6 Coccidioidomycosis
9 Global Antifungal Treatment Market, by Pathogens
9.1 Introduction
9.2 Candida
9.3 Aspergillus
9.4 Cryptococcus
9.5 Coccidioides immitis
9.6 Zygomycetes
9.7 Trichophyton
10 Global Antifungal Treatment Market, by End User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Dermatology Clinics
10.4 Others
11 Global Antifungal Treatment Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 U.K.
11.3.1.4 Italy
11.3.1.5 Spain
11.3.2 Rest of Western Europe
11.3.3 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Republic of Korea
11.4.5 Australia
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.1 The Middle East
11.5.2 Africa
12 Competitive Landscape
12.1 Introduction
12.2 Company Share Analysis
13 Company Profiles
13.1 Pfizer, Inc.
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products
13.1.4 Strategy
13.1.5 Key Achievements
13.2 Astellas
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products
13.2.4 Strategy
13.2.5 Key Achievements
13.3 Novartis AG.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products
13.3.4 Strategy
13.3.5 Key Achievements
13.4 Sanofi
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Products
13.4.4 Strategy
13.4.5 Key Achievements
13.5 Merck & Co., Inc.
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products
13.5.4 Strategy
13.5.5 Key Achievements
13.6 Bayer AG
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products
13.6.4 Strategy